Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
- Trial met primary efficacy endpoint at week 12
- EVO301 produced rapid, statistically significant EASI reductions at weeks 4, 8 and 12 versus placebo
- 33% placebo-adjusted improvement in EASI at week 12
- 23% of EVO301 patients achieved IGA 0/1 at week 12
- Company to hold conference call and webcast at 8:30 a.m. ET today
Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of
